Understanding how lung cancer adapts during treatment with targeted therapies
Mechanisms driving lung cancer evolution during targeted kinase inhibitor treatment
This study is looking at how lung cancer cells change and become resistant to certain treatments, with the goal of finding new ways to help patients avoid or delay this resistance.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10814918 on NIH RePORTER |
What this research studies
This research investigates how lung cancer cells evolve and develop resistance to targeted therapies that inhibit specific oncogenic kinases, such as EGFR and ALK. By studying the genomic changes in cancer cells that survive initial treatment, the researchers aim to identify mechanisms that contribute to drug resistance. The project utilizes both biochemical and computational methods to analyze the role of a specific enzyme, APOBEC3A, in promoting mutations that lead to treatment failure. Patients may benefit from insights that could inform new treatment strategies to prevent or delay resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are lung cancer patients with tumors harboring specific genetic alterations who are undergoing treatment with targeted kinase inhibitors.
Not a fit: Patients with lung cancer who do not have the relevant genetic alterations or who are not receiving targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for lung cancer patients, potentially improving their survival rates.
How similar studies have performed: Previous research has shown that understanding the mechanisms of drug resistance in cancer can lead to significant advancements in treatment approaches, indicating that this area of study has potential for impactful findings.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Hata, Aaron N — Massachusetts General Hospital
- Study coordinator: Hata, Aaron N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.